<DOC>
	<DOC>NCT01441661</DOC>
	<brief_summary>This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase knowledge about usage, dosage, efficacy and safety under conditions of routine use of Sunitinib.</brief_summary>
	<brief_title>Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description>Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in Chinese patients with renal cell carcinoma were deficiency. The investigators carried out this research project will be sufficient evidence, and help clinicians in China to make decision in real daily practice.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed, unresectable advanced renal cell carcinoma; Sunitinib as firstline treatment alone or combined with other therapies. History of Grade 3/4 severe allergic reaction to Sunitinib or its metabolites</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>kidney diseases</keyword>
	<keyword>urogenital neoplasms</keyword>
	<keyword>kidney cancer</keyword>
</DOC>